The FDA is reminding healthcare professionals that oral nimodipine capsules should be given only by mouth or through a nasogastric tube and should never be given by intravenous administration. Nimodipine is intended to be given in a critical care setting to treat neurologic complications from subarachnoid hemorrhage and is only available as an oral capsule. The FDA has continued to receive reports of intravenous nimodipine use which can result in death, cardiac arrest, severe falls in blood pressure, and other heart-related complications.
The Prescribing Information for nimodipine contains a Boxed Warning advising against the intravenous use of nimodipine. The product labeling also provides clear instructions on how to remove the liquid contents from the capsules for nasogastric tube administration in patients who are unable to swallow. The instructions recommend that the syringe used for withdrawal of capsule contents be labeled with “Not for IV Use.”
For more information visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm220840.htm.